Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.

Br J Cancer · 2018 · PMC6265331 · PMID 30420611

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

modestly significantno p-value reported

Discussion In this large, population-based study of older women with a history of oral bisphosphonate exposure we observed that use of denosumab was associated with a modestly significant 13% decreased risk of subsequent breast cancer.

also in 257 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.